Abstract
The aim of this study was to develop a potential selective radiopharmaceutical for the non-invasive assessment of cardiac β1-adrenoceptors in vivo. Nebivolol is a cardioselective β1-adrenergic receptor antagonist that was successfully labeled with NCA 125I via direct electrophilic substitution at ambient temperature. The reaction parameters studied were nebivolol concentration, pH of the reaction mixture and kinds of oxidizing agents. The radiolabeled compound maintained its stability throughout working period of 24 h. In vivo uptake of 125I-nebivolol in the heart was 8.51 ± 0.01% ID/organ at 0.5 h post-injection, whereas the clearance pathways from the rats appear to proceed via the hepatobiliary and renal clearance. Administration of cold nebivolol reduced the heart uptake to 2.1 ± 0.13% and further confirms the high specificity and selectivity of this radiotracer for the myocardial β1-adrenoceptors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
